

FOR IMMEDIATE RELEASE

Bio Vitos Ltd establishes FERROVITOS AB as a wholly owned Swedish subsidiary – opening new opportunities for substantial EU funding

LONDON / STOCKHOLM — 22 October 2026 — Bio Vitos Ltd ("Bio Vitos" or the "Company") is taking a strategically important step in its international development by establishing FERROVITOS AB as a 100 percent wholly owned Swedish subsidiary. The new company will be responsible for the group's Swedish research activities and creates opportunities to apply for significant research funding from the European Union.

AT A GLANCE

100 %

wholly owned Swedish subsidiary of Bio Vitos Ltd

Sweden

the group's clinical research is already conducted here

EU

opportunity to apply for research funding, including Horizon Europe

Immediately

work on EU applications starts now

— FERROVITOS AB – a new Swedish research platform

Bio Vitos Ltd, headquartered in the United Kingdom, has previously placed its clinical research in Sweden, where the Company conducts studies focused on iron deficiency, iron absorption and the development of future iron treatments.

The establishment of FERROVITOS AB creates a long-term Swedish platform for research and development. The Swedish subsidiary will run the Swedish part of the group's research activities and act as a central player in future research projects.

Bio Vitos Ltd

Parent company · United Kingdom



100% ownership

FERROVITOS AB

Subsidiary · Sweden · research and development

— FERROVITOS AB opens the door to substantial EU funding

One of the most important reasons for the establishment is that FERROVITOS AB, as a Swedish company within the EU, can apply for research funding through relevant European support

programmes. The EU invests significant amounts in medical research, innovation and the development of new treatment methods through, among other things, the Horizon Europe research programme.

Through FERROVITOS AB, Bio Vitos gains a clear organisational platform within the EU from which to seek these research funds. Bio Vitos will therefore begin work immediately on applications for EU funding through FERROVITOS AB for the group's upcoming research projects.

The goal is to attract significant research grants that can help finance and accelerate continued clinical research.

— FE-MININ and MAXFERMAN form the foundation for further research

Bio Vitos has already established extensive research activities in Sweden. The Company's research programme includes, among other things:

FE-MININ

Clinical study focused on iron treatment in women.

MAXFERMAN

Upcoming clinical study of 80 men aged 25 to 55, with planned start on 15 January 2027.

Future projects

Further development of treatments and research on iron deficiency, iron absorption and new medical applications.

The research is conducted in collaboration with medical and academic expertise, including Professor Fredrik Nyström at Linköping University. Through FERROVITOS AB, the group wants to further strengthen cooperation with Swedish and European universities, research institutions and medical organisations.

— A strategic opportunity for Bio Vitos and its shareholders

The establishment of FERROVITOS AB is an important opportunity to broaden the funding of Bio Vitos' future research. By applying for European research grants, parts of upcoming clinical studies could potentially be funded without the Company having to contribute corresponding amounts through new share issues.

This could mean a reduced need for external equity financing, greater financial flexibility and improved conditions for long-term value creation for Bio Vitos' shareholders. The Swedish subsidiary thus becomes an important part of the group's continued research strategy and international expansion.

“The establishment of FERROVITOS AB as a 100 percent wholly owned Swedish subsidiary of Bio Vitos Ltd is a very important strategic step for our group. Since our clinical research is already conducted in Sweden, it is natural that we now create a Swedish corporate structure that can be responsible for the research while also giving us the opportunity to seek substantial research funding from the EU.

We will immediately begin work on applications for EU funds for our upcoming research projects. This is particularly interesting because successful applications could give us access to significant research capital without having to finance all of the research through new share issues.

Our ambition is for FERROVITOS AB to develop into a strong Swedish research platform in iron deficiency and iron treatment, with access to both Swedish and European research expertise. We see this as the beginning of a very exciting new phase for Bio Vitos and our shareholders.”

— Cato Crogh, Chairman of the Board, Bio Vitos Ltd

— Next steps – EU applications start immediately

FERROVITOS AB will now prioritise identifying relevant European research programmes and preparing applications for upcoming clinical studies.

01

Identify relevant European research programmes.

02

Prepare applications for upcoming clinical studies.

03

Develop collaborations with universities, research institutions and European innovation organisations.

The goal is to establish FERROVITOS AB as a long-term Swedish research platform while creating new funding opportunities for Bio Vitos’ continued development. The possibility of obtaining EU funding depends on the terms of each support programme and on applications being approved. No research grants are guaranteed.

— About FERROVITOS AB

FERROVITOS AB is a 100 percent wholly owned Swedish subsidiary of Bio Vitos Ltd, focused on research and development in iron deficiency, iron absorption and future iron treatments. The company will be responsible for the group’s Swedish research activities and will work on applications for national and European research funding.

###

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements that involve risks and uncertainties, including regarding the possibility of obtaining EU funding, the terms of each support programme, approval of applications, the timing and conduct of upcoming clinical studies and their outcomes. The statements are based on current expectations and assumptions, and actual outcomes may differ materially. No research grants are guaranteed. The Company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

ABOUT BIO VITOS LTD

Bio Vitos Ltd is a UK company focused on research and development in iron deficiency and iron treatment. The Company’s product SUCCIFER® is based on the iron compound ferrous succinate. Through clinical studies in Sweden, Bio Vitos works to develop knowledge of iron absorption and future treatment options.

MEDIA AND INVESTOR CONTACT

Cato Crogh, Chairman of the Board, Bio Vitos Ltd
E-mail: info@biovitos.com
Web: www.biovitos.com